Pruc M

Institute of Medical Science, Collegium Medicum, The John Paul II Catholic University of Lublin, Lublin, Poland.

7 papers · ORCID

ArticlePsilocybin

Cardiovascular safety of psilocybin in psychiatric practice: a narrative review.

Szarpak L, Pruc M, Swieczkowski D +3

Europe PMC2026
ArticleKetamine

Addressing diversity gaps in esketamine clinical trials: a registry-based cross-sectional analysis of sex, race and ethnicity.

Swieczkowski D, Kwaśny A, Pruc M +2

Europe PMC2026
ArticlePsilocybin

Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics.

Swieczkowski D, Kwaśny A, Ciurkowska P +3

Europe PMC2025
ArticleKetamine

Lessons learned from the regulatory alignment in ketamine, esketamine and arketamine clinical trials: A cross-sectional analysis of protocols from ClinicalTrials.gov.

Swieczkowski D, Kwaśny A, Sadko K +4

Europe PMC2025
ArticlePsilocybin

Psilocybin-assisted psychotherapy as a rapid-acting treatment for cancer-related depression and anxiety: Evidence from a network meta-analysis.

Swieczkowski D, Kwaśny A, Pruc M +3

Europe PMC2025
ArticlePsilocybin

Regulatory Alignment of Psilocybin Clinical Trials in Major Depressive Disorder on ClinicalTrials.gov: A Cross-Sectional Analysis.

Swieczkowski D, Kwaśny A, Pruc M +3

Europe PMC2025
ArticlePsilocybin

Efficacy and safety of psilocybin in the treatment of Major Depressive Disorder (MDD): A dose-response network meta-analysis of randomized placebo-controlled clinical trials.

Swieczkowski D, Kwaśny A, Pruc M +3

Europe PMC2025